EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD

EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering

February 1, 2021 4:04 PM EST

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market... More

After-Hours Stock Movers 01/27: (EYPT) (AGTC) (NOW) Higher; (AMC) (AXDX) (EXPR) Lower (more...)

January 27, 2021 6:05 PM EST

After-Hours Movers

AMC Entertainment Holdings, Inc. (NYSE: AMC) 25.4% LOWER; profit-taking after rising 301% intra-day Wednesday on short-squeeze

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 9% HIGHER; Cantor Fitzgerald initiates with an Overweight rating and price target of $22.00.

Accelerate... More

Cantor Fitzgerald Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Overweight

January 27, 2021 4:03 PM EST

Cantor Fitzgerald analyst Jennifer Kim initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with an Overweight rating and price target of $22.00.

The analyst comments "We are initiating coverage of EYPT shares with an Overweight rating and a 12-month PT of $22 using DCF analysis.... More